Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016

  • ID: 3774309
  • Drug Pipelines
  • 179 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Astrazeneca, Inc.
  • Chidamide
  • Chipscreen Biosciences
  • Curis Inc.
  • Novartis Pharmaceuticals
  • MORE
“Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016” provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Estrogen Receptor Positive (ER+) Breast Cancer. The report provides the in-depth analysis of the pipeline assets across the Estrogen Receptor Positive (ER+) Breast Cancer. The Report gives insights on 40+ products. It also includes around 30+ companies which are active in this field.

Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Estrogen Receptor Positive (ER+) Breast Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Estrogen Receptor Positive (ER+) Breast Cancer.

These days’ companies are focusing on the Targeted Therapy for cancer. Ipsen’s Triptorelin pamoate is the Gonadotropin-releasing hormone (GnRH) Agonist in Phase III stage, Seattle Genetics’s SGN-LIV1A, is a monoclonal antibody in Phase I are competing against other small molecules. Many big pharmaceuticals companies are involved in ER Breast Cancer. Compared to other cancers, breast cancers show marked resistance to conventional forms of chemotherapy, and there are limited capabilities to diagnose and treat the disease in its earliest stages. No current treatment option has demonstrated long-term benefit in patients with advanced disease who are not eligible for surgery, which represents the majority (80%) of breast cancer cases. Recent report of our covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
- The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
- Coverage of the Estrogen Receptor Positive (ER+) Breast Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for ER Positive Breast Cancer and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Astrazeneca, Inc.
  • Chidamide
  • Chipscreen Biosciences
  • Curis Inc.
  • Novartis Pharmaceuticals
  • MORE
Table of Contents

- Breast cancer Overview
- Signs and symptoms
- Diagnosis
- Treatment
- Breast Cancer Trends and Future Prospects
- Market Barriers
- Market Drivers
- Pipeline Therapeutics
- Therapeutics under Development by Companies
- Last Stage Products (Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Product Description
- Research and Development
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products
- Comparative Analysis
- Discontinued Products
- Comparative Analysis
- Companies Involved in Therapeutic Development
- Appendix
- Methodology
- Consulting Services
- About us
- Contact Us
- Disclaimer

List of Tables

- Table 1:Number of Products Under Development for Estrogen Receptor Positive (ER+) Breast Cancer , 2016
- Table 2: Number of Products under Development by Companies, 2016
- Table 3: Last Stage Products (Phase III and Filed),2016
- Table 4: Mid Stage Products (Phase II), 2016
- Table 5: Early Stage Products (Phase I and IND), 2016
- Table 6: Assessment by Monotherapy Products, 2016
- Table 7:Assessment by Route Of Administration, 2016
- Table 8:Assessment by Stage and Route Of Administration, 2016
- Table 9:Assessment by Molecule Type, 2016
- Table 10:Assessment by Stage and Molecule Type, 2016
- Table 11:Dormant Products, 2016
- Table 12: Discontinued Products
- Table 13: Companies under development for therapeutic drugs, 2016

List of Figures
- Figure 1:Treatment Algorithm for Breast Cancer, 2016
- Figure 2: Number of Products under Development for Estrogen Receptor Positive (ER+) Breast Cancer ,2016
- Figure 3:Last Stage Products (Phase III), 2016
- Figure 4: Mid Stage Products (Phase II),2016
- Figure 5: Early Stage Products (Phase I and IND), 2016
- Figure 6: Assessment by Monotherapy Products, 2016
- Figure 7: Assessment by Route of Administration, 2016
- Figure 8: Assessment by Stage and Route of Administration, 2016
- Figure 9: Assessment by Molecule Type, 2016
- Figure 10:Assessment by Stage and Molecule Type, 2016
- Figure 11:Dormant Products, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Sanofi-Aventis
- Astellas Pharma
- Pfizer Inc.
- Novartis Pharmaceuticals
- Astrazeneca, Inc.
- Curis Inc.
- Chidamide
- Chipscreen Biosciences
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll